Xvivo Perfusion Ab Stock Today
| XVIPF Stock | USD 41.23 0.77 1.83% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Xvivo Perfusion is trading at 41.23 as of the 22nd of November 2024. This is a 1.83% down since the beginning of the trading day. The stock's lowest day price was 40.55. Xvivo Perfusion has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Xvivo Perfusion AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company has 29.83 M outstanding shares. More on Xvivo Perfusion AB
Moving together with Xvivo Pink Sheet
Moving against Xvivo Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Xvivo Pink Sheet Highlights
| Deputy CEO, CFO | Christoffer Rosenblad |
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
Xvivo Perfusion AB [XVIPF] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 674.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Xvivo Perfusion's market, we take the total number of its shares issued and multiply it by Xvivo Perfusion's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Xvivo Perfusion AB classifies itself under Healthcare sector and is part of Medical Devices industry. The entity has 29.83 M outstanding shares.
Xvivo Perfusion AB has accumulated about 22.66 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86.
Check Xvivo Perfusion Probability Of Bankruptcy
Ownership AllocationXvivo Perfusion AB retains a total of 29.83 Million outstanding shares. Over half of Xvivo Perfusion's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Xvivo Ownership Details
Xvivo Perfusion AB Risk Profiles
| Mean Deviation | 1.08 | |||
| Standard Deviation | 1.94 | |||
| Variance | 3.76 | |||
| Risk Adjusted Performance | (0.08) |
Xvivo Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Xvivo Perfusion without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Xvivo Perfusion Corporate Management
| Jaya Tiwari | VP Affairs | Profile | |
| Magnus Nilsson | Advisor | Profile | |
| Katrin Gisselfalt | Global Director | Profile | |
| Charlotte Walldal | Global director | Profile | |
| Lena BSc | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Johan Holmstrom | Chief Officer | Profile |
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.